Skip Navigation


Journal of the National Cancer Institute Advance Access originally published online on January 8, 2008
JNCI Journal of the National Cancer Institute 2008 100(2):79; doi:10.1093/jnci/djn002
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
100/2/79-b    most recent
djn002v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Savage, L.
Right arrow Articles by Widener, A.
Related Collections
Right arrowRelated Article in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© Oxford University Press 2008.

MEMO TO THE MEDIA

Docetaxel Given After Doxorubicin Reduces Recurrence

Liz Savage, Andrea Widener

jncimedia@oxfordjournals.org
301-841-1287

The first 10% of the full text of this article appears below.

Adding the drug docetaxel to anthracycline-based chemotherapy slightly improved disease-free survival in breast cancer patients, according to a randomized clinical trial published online January 8 in the Journal of the National Cancer Institute.

Docetaxel has previously . . . [Full Text of this Article]

Contact:

Citations:

Note to Reporters:


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Article in JNCI

Adjuvant Chemotherapy With Sequential or Concurrent Anthracycline and Docetaxel: Breast International Group 02–98 Randomized Trial
Prudence Francis, John Crown, Angelo Di Leo, Marc Buyse, Ana Balil, Michael Andersson, Bo Nordenskjöld, Istvan Lang, Raimund Jakesz, Daniel Vorobiof, Jorge Gutiérrez, Guy van Hazel, Stella Dolci, Sophie Jamin, Belguendouz Bendahmane, Richard D. Gelber, Aron Goldhirsch, Monica Castiglione-Gertsch, and Martine Piccart-Gebhart On behalf of the BIG 02-98 Collaborative Group
J Natl Cancer Inst 2008 100: 121-133. [Abstract] [Full Text] [PDF]